Amphastar Pharmaceuticals Inc Forecast, price target & analysts
Why the stock moved Beta
Amphastar Pharmaceuticals Inc Target price 2026 - Analyst rating & recommendation
Amphastar Pharmaceuticals Inc Classifications & Recommendation
Amphastar Pharmaceuticals Inc Price Target
| Target Price | $21.42 |
| Price | $26.27 |
| Deviation |
18.46%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Amphastar Pharmaceuticals Inc 2027 .
The average Amphastar Pharmaceuticals Inc target price is $21.42.
This is
18.46%
register free of charge
$31.50
19.91%
register free of charge
$20.20
23.11%
register free of charge
|
|
| A rating was issued by 12 analysts: 0 Analysts recommend Amphastar Pharmaceuticals Inc to buy, 8 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Amphastar Pharmaceuticals Inc stock has an average upside potential 2027 of
18.46%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2031
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 719.89 | 764.39 |
| 1.65% | 6.18% | |
| EBITDA Margin | 21.53% | 28.22% |
| 27.67% | 31.06% | |
| Net Margin | 13.63% | 16.84% |
| 37.48% | 23.59% |
9 Analysts have issued a sales forecast Amphastar Pharmaceuticals Inc 2026 . The average Amphastar Pharmaceuticals Inc sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Amphastar Pharmaceuticals Inc EBITDA forecast 2026. The average Amphastar Pharmaceuticals Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Amphastar Pharmaceuticals Inc Analysts have issued a net profit forecast 2026. The average Amphastar Pharmaceuticals Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2031
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.03 | 3.03 |
| 33.66% | 49.26% | |
| P/E | 8.68 | |
| EV/Sales | 1.88 |
9 Analysts have issued a Amphastar Pharmaceuticals Inc forecast for earnings per share. The average Amphastar Pharmaceuticals Inc EPS is
This results in the following potential growth metrics and future valuations:
Amphastar Pharmaceuticals Inc...
Current Amphastar Pharmaceuticals Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Barclays |
Locked
➜
Locked
|
Locked | Aug 18 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| B of A Securities |
Locked
➜
Locked
|
Locked | Jun 29 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Jun 03 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | May 14 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | May 11 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Barclays:
Locked
➜
Locked
|
Aug 18 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
B of A Securities:
Locked
➜
Locked
|
Jun 29 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Jun 03 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
May 14 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
May 11 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
